Fukui M, Nakamura N, Nakano K, Kajiyama S, Matsuo S, Obayashi H, Ohta M, Shigeta M, Shigeta H, Kitagawa Y, Kondo M
The First Department of Internal Medicine, Kyoto Prefectural University of Medicine, Japan.
Endocr J. 2000 Dec;47(6):753-61. doi: 10.1507/endocrj.47.753.
Proliferative response of peripheral blood mononuclear cells (PBMC) to glutamic acid decarboxylase (GAD), which has been reported in patients with type 1 diabetes, was measured in type 2 diabetes, especially in patients with antibodies to GAD initially diagnosed as having type 2 diabetes (anti-GAD+ type 2 diabetes). We studied 12 patients with type 1 diabetes, 22 with anti-GAD+ type 2 diabetes, 31 with type 2 diabetes who were negative for anti-GAD (anti-GAD+ type 2 diabetes), and 30 healthy control subjects for cellular responses in vitro to GAD. The mean stimulation index (SI) in response to GAD was significantly higher in type 1 diabetes than in anti-GAD+ type 2 diabetes or healthy controls (1.47+/-0.35 vs. 1.11+/-0.35, P<0.05, and 1.06+/-0.07, P<0.05, respectively). The mean
在2型糖尿病患者中，尤其是最初被诊断为2型糖尿病的谷氨酸脱羧酶抗体阳性患者（抗GAD + 2型糖尿病）中，检测了外周血单核细胞（PBMC）对谷氨酸脱羧酶（GAD）的增殖反应，而这种反应在1型糖尿病患者中已有报道。我们研究了12例1型糖尿病患者、22例抗GAD + 2型糖尿病患者、31例抗GAD阴性的2型糖尿病患者（抗GAD - 2型糖尿病）以及30名健康对照者，以观察其细胞在体外对GAD的反应。1型糖尿病患者对GAD反应的平均刺激指数（SI）显著高于抗GAD + 2型糖尿病患者或健康对照者（分别为1.47±0.35对1.11±0.35，P<0.05；以及1.06±0.07，P<0.05）。平均……
